Healthcare - Biotechnology - NASDAQ - US
$ 63.42
-3.32 %
$ 12.1 B
Market Cap
38.91
P/E
INCOME STATEMENT
2.42 B
REVENUE
194 M
OPERATING INCOME
168 M
NET INCOME
EFFICIENCY
Earnings Waterfall
BioMarin Pharmaceutical Inc.
| Revenue | 2.42 B |
| Cost Of Revenue | 515 M |
| Gross Profit | 1.9 B |
| Operating Expenses | 1.75 B |
| Operating Income | 194 M |
| Other Expenses | 26.8 M |
| Net Income | 168 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | Dec-2012 | Dec-2011 | Dec-2010 | Dec-2009 | Dec-2008 | Dec-2007 | Dec-2006 | Dec-2005 | Dec-2004 | Dec-2003 | Dec-2002 | Dec-2001 | Dec-2000 | Dec-1999 | Dec-1998 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||||||||||||||||
| Revenue | 2 419.2 | 2 096.0 | 1 846.3 | 1 860.5 | 1 704.0 | 1 491.2 | 1 313.6 | 1 116.9 | 889.9 | 751.0 | 548.5 | 500.7 | 441.4 | 376.3 | 324.7 | 296.5 | 121.6 | 84.2 | 25.7 | 18.6 | 12.1 | 13.9 | 11.7 | 12.3 | 7.0 | 1.2 |
| GROSS PROFIT | ||||||||||||||||||||||||||
| Cost Of Revenue | 514.9 | 483.7 | 470.5 | 524.3 | 359.5 | 315.3 | 241.8 | 209.6 | 152.0 | 129.8 | 95.7 | 91.8 | 84.0 | 70.3 | 65.9 | 52.5 | 18.4 | 8.7 | 2.6 | 4.0 | 0 | 0 | 0 | (6.6) | (6.1) | (0.7) |
| Gross Profit | 1 904.4 | 1 612.4 | 1 375.8 | 1 336.2 | 1 344.6 | 1 175.9 | 1 071.9 | 907.2 | 737.9 | 621.3 | 452.7 | 408.9 | 357.3 | 306.0 | 258.7 | 244.0 | 103.2 | 75.5 | 23.0 | 14.7 | 12.1 | 13.9 | 11.7 | 18.9 | 13.1 | 1.9 |
| OPERATING INCOME | ||||||||||||||||||||||||||
| Operating Expenses | 1 746.3 | 1 570.8 | 1 458.1 | 1 432.4 | 1 470.0 | 1 349.5 | 1 211.6 | 1 111.5 | 1 019.4 | 781.7 | 608.8 | 519.1 | 389.8 | 299.0 | 242.3 | 204.2 | 160.5 | 100.1 | 87.3 | 162.6 | 87.9 | 81.5 | 52.0 | 51.9 | 40.6 | 14.8 |
| Selling, General and Administrative Expenses | 937.3 | 854.0 | 759.4 | 737.7 | 680.9 | 604.4 | 554.3 | 476.6 | 402.3 | 302.2 | 235.4 | 198.2 | 175.4 | 151.7 | 124.3 | 106.6 | 77.5 | 49.0 | 41.6 | 37.6 | 14.4 | 17.5 | 6.7 | 8.8 | 6.8 | 3.5 |
| Research and Development Expenses | 746.8 | 649.6 | 628.8 | 628.1 | 715.0 | 696.3 | 610.8 | 661.9 | 634.8 | 461.5 | 354.8 | 302.2 | 214.4 | 147.3 | 115.1 | 93.3 | 78.6 | 66.7 | 56.4 | 49.8 | 54.8 | 54.5 | 45.3 | 35.8 | 27.2 | 10.5 |
| Operating Income | 194.4 | 57.5 | (60.0) | (96.3) | (125.5) | (123.5) | (14.7) | (803.4) | (110.7) | (92.9) | (156.0) | (110.2) | (33.9) | 0.5 | 16.4 | 39.8 | (57.3) | (24.7) | (64.2) | (179.4) | (75.8) | (78.8) | (51.9) | (33.0) | (27.5) | (12.9) |
| PRE-TAX INCOME | ||||||||||||||||||||||||||
| Interest Income Expense | 17.3 | 16.0 | 15.3 | 29.3 | 23.5 | 43.7 | 42.7 | 39.5 | 38.2 | 36.6 | 10.4 | 7.6 | 8.3 | 10.3 | 14.1 | 16.4 | (14.2) | 16.7 | 11.9 | (10.5) | 3.1 | (0.5) | 0 | 7 K | 0 | 0 |
| Total Other Income | (5.9) | 14 K | (15.3) | (5.6) | 5.6 | (19.2) | (35.9) | (27.6) | (44.0) | (32.0) | (20.5) | (8.1) | (9.7) | (22.0) | (15.9) | (6.3) | 42.2 | (3.9) | (10.1) | (8.1) | 5 K | 1.4 | (19.0) | (7.3) | (3.4) | 0.6 |
| Pre-Tax Income | 188.6 | 149.6 | (75.3) | (42.3) | (94.8) | (142.7) | (35.9) | (831.0) | (154.7) | (124.9) | (176.5) | (118.3) | (43.6) | (21.5) | 0.6 | 33.4 | (15.1) | (28.5) | (74.3) | (187.4) | (75.8) | (77.5) | (70.9) | (40.3) | (29.2) | (12.3) |
| NET INCOME | ||||||||||||||||||||||||||
| Tax Provision | 20.9 | 8.0 | (11.3) | (901.4) | (71.0) | (65.5) | 81.2 | (200.8) | 17.1 | 9.1 | (0.1) | (3.9) | 10.2 | (227.3) | 1.1 | 2.6 | 0.7 | 23.1 | 21.9 | 36.6 | 5 K | 9.8 | 20.0 | 4.4 | 0.6 | (0.6) |
| Net Income | 167.6 | 141.6 | (64.1) | 854.0 | (23.8) | (77.2) | (117.0) | (630.2) | (171.8) | (134.0) | (176.4) | (114.3) | (53.8) | 205.8 | (0.5) | 30.8 | (15.8) | (28.5) | (74.3) | (187.4) | (75.8) | (77.5) | (67.6) | (37.4) | (28.1) | (12.3) |
| EPS | 0.89 | 0.76 | 0.35 | 4.75 | 0.13 | 0.44 | 0.67 | 3.8 | 1.07 | 0.92 | 1.28 | 0.95 | 0.48 | 1.99 | 0.0049 | 0.31 | 0.16 | 0.34 | 1.08 | 2.91 | 1.22 | 1.45 | 1.65 | 1.04 | 0.94 | 0.55 |